• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Psoriatic Arthritis - Pipeline Review, Q1 2011 - Product Image

Psoriatic Arthritis - Pipeline Review, Q1 2011

  • ID: 1574100
  • March 2011
  • 37 pages
  • Global Markets Direct

Psoriatic Arthritis - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Psoriatic Arthritis - Pipeline Review, Q1 2011', provides an overview of the Psoriatic Arthritis therapeutic pipeline. This report provides information on the therapeutic development for Psoriatic Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psoriatic Arthritis. 'Psoriatic Arthritis - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Psoriatic Arthritis.
- A review of the Psoriatic Arthritis products under development by companies and universities/research READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Psoriatic Arthritis Overview
Therapeutics Development
An Overview of Pipeline Products for Psoriatic Arthritis
Psoriatic Arthritis Therapeutics under Development by Companies
Psoriatic Arthritis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Psoriatic Arthritis Therapeutics Development
F. Hoffmann-La Roche Ltd.
Novartis AG
Astellas Pharma Inc.
Cephalon, Inc.
Pfizer Inc.
UCB Group
Celgene Corporation
Txcell SA
Allostera Pharma Inc.
Universities/Institutes Involved in Psoriatic Arthritis Therapeutics Development
Psoriatic Arthritis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Apremilast - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cimzia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Psoriatic Arthritis - Featured News
1. Nov 11, 2010: Centocor Ortho Biotech Submits sBLA Application To FDA Seeking To Expand SIMPONI Label
2. Apr 24, 2008: Centocor Ortho Biotech Inc. Receives FDA Approval For Golimumab (SIMPONI)As First Once-Monthly Anti-TNF For Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Psoriatic Arthritis, 2011
Products under Development for Psoriatic Arthritis – Comparative Analysis, 2011
Comparative Analysis by Late Stage Development, 2011
Comparative Analysis by Mid Clinical Stage Development, 2011
Comparative Analysis by Early Clinical Stage Development, 2011
Comparative Analysis by Pre-Clinical Stage Development, 2011
F. Hoffmann-La Roche Ltd., 2011
Novartis AG, 2011
Astellas Pharma Inc., 2011
Cephalon, Inc., 2011
Pfizer Inc., 2011
UCB Group, 2011
Celgene Corporation, 2011
Txcell SA, 2011
Allostera Pharma Inc., 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Discontinued Products

List of Figures
Number of Products under Development for Psoriatic Arthritis, 2011
Products under Development for Psoriatic Arthritis – Comparative Analysis, 2011
Products under Development by Companies, 2011
Products under Investigation by Universities/Institutes, 2011
Late Stage Products, 2011
Mid Clinical Stage Products, 2011
Early Clinical Stage Products, 2011
Pre-Clinical Stage Products, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products, 2011
Assessment by Route of Administration, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Assessment by Stage and Molecule Type, 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos